Drug intelligence / Profile preview

WTPA

Development stage: Unknown
Lead developer: Beijing Wanter Bio-pharmaceutical
Administration: Subcutaneous, Intramuscular, Intravesical

Overview

WTPA is an immunotherapy based on a *Pseudomonas aeruginosa* injection, developed by Beijing Wanter Bio-pharmaceutical Co. Ltd. It is being investigated as an adjuvant therapy for various cancers, including HER-2 negative locally advanced breast cancer, renal cell carcinoma, and non-muscle-invasive bladder cancer. Its mechanism of action involves activating the immune system to inhibit tumor cell proliferation.

Brand names: 万特普安

Beyond the preview

Go deeper on WTPA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WTPA.

Explore the full profile